206 related articles for article (PubMed ID: 28976433)
1. T-Score Discordance of Bone Mineral Density in Patients with Atypical Femoral Fracture.
Lee KJ; Min BW; Song KS; Bae KC; Cho CH; Lee SW
J Bone Joint Surg Am; 2017 Oct; 99(19):1683-1688. PubMed ID: 28976433
[TBL] [Abstract][Full Text] [Related]
2. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy.
Clout A; Narayanasamy N; Harris I
J Orthop Surg (Hong Kong); 2016 Apr; 24(1):36-40. PubMed ID: 27122510
[TBL] [Abstract][Full Text] [Related]
3. Trabecular Bone Score and Hip Structural Analysis in Patients With Atypical Femur Fractures.
Buitendijk SKC; van de Laarschot DM; Smits AAA; Koromani F; Rivadeneira F; Beck TJ; Zillikens MC
J Clin Densitom; 2019; 22(2):257-265. PubMed ID: 29661684
[TBL] [Abstract][Full Text] [Related]
4. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan.
Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078
[TBL] [Abstract][Full Text] [Related]
5. Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea.
Lee YK; Ahn S; Kim KM; Suh CS; Koo KH
J Korean Med Sci; 2018 Jan; 33(5):e38. PubMed ID: 29349947
[TBL] [Abstract][Full Text] [Related]
6. Critical differences between subtrochanteric and diaphyseal atypical femoral fractures: analyses of 51 cases at a single institution in Korean population.
Cho YJ; Kang KC; Chun YS; Rhyu KH; Kim SJ; Jang TS
Arch Osteoporos; 2018 May; 13(1):53. PubMed ID: 29725835
[TBL] [Abstract][Full Text] [Related]
7. Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study.
Koh JH; Myong JP; Jung SM; Lee J; Kwok SK; Park SH; Ju JH
Arthritis Rheumatol; 2016 Jan; 68(1):77-82. PubMed ID: 26360133
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis.
Wong CH; Kan AKC; Tsoi KH; Chan SSY; Jiang NS; Loong CHN; Fong CHY; Wong JSH; Shea GKH; Cheung CL; Lee CH; Tan KCB; Woo YC; Lui DTW
Endocrine; 2024 Apr; 84(1):223-235. PubMed ID: 37985574
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy.
Franceschetti P; Bondanelli M; Caruso G; Ambrosio MR; Lorusso V; Zatelli MC; Massari L; Degli Uberti EC
Bone; 2013 Oct; 56(2):426-31. PubMed ID: 23871850
[TBL] [Abstract][Full Text] [Related]
10. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur.
Greenspan SL; Vujevich K; Britton C; Herradura A; Gruen G; Tarkin I; Siska P; Hamlin B; Perera S
Osteoporos Int; 2018 Feb; 29(2):501-506. PubMed ID: 29085957
[TBL] [Abstract][Full Text] [Related]
11. Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study.
Eisenstein N; Kasavkar G; Bhavsar D; Khan FS; Paskins Z
BMC Musculoskelet Disord; 2017 Jan; 18(1):29. PubMed ID: 28114975
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates and the risk of atypical femur fractures.
Black DM; Condra K; Adams AL; Eastell R
Bone; 2022 Mar; 156():116297. PubMed ID: 34920168
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate treatment and the risk of atypical femoral fracture among patients participating in a Fracture Liaison Service of a tertiary medical center.
Bareli N; Gat R; Makarov V; Siris E; Fraenkel M; Yoel U
Arch Osteoporos; 2021 Jun; 16(1):86. PubMed ID: 34089098
[TBL] [Abstract][Full Text] [Related]
14. Lateral Cortical Thickening and Bone Heterogeneity of the Subtrochanteric Femur Measured With Quantitative CT as Indicators for Early Detection of Atypical Femoral Fractures in Long-Term Bisphosphonate Users.
Lee SH; Lee YH; Suh JS
AJR Am J Roentgenol; 2017 Oct; 209(4):867-873. PubMed ID: 28796551
[TBL] [Abstract][Full Text] [Related]
15. Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years.
Lo JC; Neugebauer RS; Ettinger B; Chandra M; Hui RL; Ott SM; Grimsrud CD; Izano MA
BMC Musculoskelet Disord; 2020 Dec; 21(1):801. PubMed ID: 33272248
[TBL] [Abstract][Full Text] [Related]
16. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
Nasomyont N; Hornung LN; Gordon CM; Wasserman H
Bone; 2019 Apr; 121():60-67. PubMed ID: 30616029
[TBL] [Abstract][Full Text] [Related]
17. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy.
Lo JC; Hui RL; Grimsrud CD; Chandra M; Neugebauer RS; Gonzalez JR; Budayr A; Lau G; Ettinger B
Bone; 2016 Apr; 85():142-7. PubMed ID: 26769007
[TBL] [Abstract][Full Text] [Related]
18. Audit of Atypical Femoral Fractures and a Description of Some of Their Features.
Lian K; Trollip J; Sandhu S; Moosavi M; Gill A; Kendler D; Dian L; Lentle B
Can Assoc Radiol J; 2016 Feb; 67(1):69-75. PubMed ID: 26800621
[TBL] [Abstract][Full Text] [Related]
19. Frequency and associated factor of atypical periprosthetic femoral fracture after hip arthroplasty.
Lee YK; Park CH; Kim KC; Hong SH; Ha YC; Koo KH
Injury; 2018 Dec; 49(12):2264-2268. PubMed ID: 30245278
[TBL] [Abstract][Full Text] [Related]
20. Retrospective review of patients with atypical bisphosphonate related proximal femoral fractures.
Phillips HK; Harrison SJ; Akrawi H; Sidhom SA
Injury; 2017 Jun; 48(6):1159-1164. PubMed ID: 28410753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
